Related Experiment Videos
Hematologic and systemic toxicoses associated with carboplatin administration in cats
K A Hahn1, M F McEntee, G B Daniel
1Department of Comparative Medicine, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071, USA.
American Journal of Veterinary Research
|June 1, 1997
Summary
Carboplatin is safe for cats at 200 mg/m2, with neutropenia as the main toxicity. This dose is recommended for further studies in tumor-bearing cats.
Area of Science:
- Veterinary Oncology
- Pharmacology
Background:
- Carboplatin is a platinum-based chemotherapy drug.
- Its use in cats requires understanding dose-limiting toxicities.
Purpose of the Study:
- To determine the prevalence and severity of carboplatin-induced toxicities in cats.
- To establish a safe and effective dosage for potential use in feline cancer treatment.
Main Methods:
- Nine healthy cats received single intravenous doses of carboplatin at 150, 200, or 250 mg/m2.
- Cats were monitored for 28 days for adverse effects and hematological changes.
Main Results:
- Dose-limiting neutropenia and thrombocytopenia were observed at 200 and 250 mg/m2.
- The neutrophil nadir occurred on day 17 and platelet nadir on day 14 at the highest dose.
- No significant weight loss, appetite changes, respiratory distress, vomiting, diarrhea, or lethargy were noted.
Conclusions:
- Carboplatin at 200 mg/m2 is safe and well-tolerated in clinically normal cats.
- Neutropenia is the dose-limiting toxicity, with nadir around day 17.
- A dose of 200 mg/m2 every 4 weeks is suggested for further investigation in tumor-bearing cats.